

March 29, 2018  
Sanyo Chemical Industries, Ltd.

## **Capital Investment to Bio-Venture Company; Delta-Fly Pharma, Inc.**

Sanyo Chemical Industries, Ltd. (HQ: Kyoto, Japan, President: Takao Ando) has made a capital investment to Delta-Fly Pharma Inc. (HQ: Tokushima, Japan, President: Kiyoshi Eshima) on March 23<sup>rd</sup>, 2018 through a third-party allotment of shares. Also both companies made the Collaboration Agreement for the Development of Novel Oncology Products innovative for cancer patients dated March 28<sup>th</sup>, 2018. Delta-Fly Pharma Inc. is a bio-pharmaceutical venture company which is developing the novel anti-cancer agents to reduce physical and economic burden of patients.

Sanyo Chemical and Delta-Fly Pharma, Inc. (DFP) have cooperatively developed the anti-cancer agents free of adverse reaction, integrated by the Drug Delivery System (DDS) technology of DFP with Polymer Technology of Sanyo Chemical. This investment and collaboration will further advance the development. The first anti-cancer agent of this collaboration is planning to start the clinical study in the US by the end of this year.

Sanyo Chemical established Biotechnology & Medical Division in April, 2017 in order to accelerate business promotion in the Bio-Medical field. This investment and collaboration is one of the endeavors. Sanyo Chemical will promote new business such as DDS without persisting in the frame of existing business.

### **ABOUT DELTA-FLY PHARMA**

Delta-Fly Pharma, Inc. is a privately held bio-pharmaceutical company established in 2010 with headquarters in Tokushima, Japan. The company is engaged in the research and development of drugs for the cancer treatment.